Aureus Pharma Extends Its Knowledge Database Agreement with Sanofi-Aventis R&D

PARIS--(Business Wire)--
Aureus Pharma, a leading provider of knowledge management solutions to
accelerate discovery in the life sciences industry, announces today the
extension of its knowledge database agreement with sanofi-aventis research &
development for an additional three-year term.

Under the agreement, Aureus will provide new AurSCOPE knowledge databases and
continue to update existing databases for sanofi-aventis` R&D division. The
Aureus Pharma databases will give sanofi-aventis researchers access to
information on major therapeutic targets. These include GPCR protein receptors,
nuclear receptors, kinase inhibitors, ion channels, as well as information
relative to drug safety including data on ADME (absorption, distribution,
metabolism, and excretion).

The new agreement reinforces the relationship between Aureus Pharma and
sanofi-aventis, which has been in existence for seven years already. It also
secures additional revenues for Aureus over the next three years.

"Sanofi-aventis` decision to extend the partnership for an additional three year
period, as well as to acquire new knowledge bases, confirms the fact that
Aureus` products are meeting the needs of the world`s leading pharmaceutical
companies," said Dr Jason Theodosiou, CEO of Aureus Pharma.

Aureus Pharma`s information solutions are working for many of the world`s most
successful biopharmaceutical companies and prestigious research institutions.

About Aureus Pharma

Aureus Pharma, provides a range of scientific knowledge solutions enabling
biopharmaceutical companies to better understand the relationships of biological
targets to compounds under evaluation. Aureus experts continuously monitor and
organize the most relevant information from the scientific literature, including
experimental in vitro and in vivo protocols. This detailed knowledge forms the
AurSCOPE® database line, focusing on the human body`s main therapeutic targets:
GPCRs, Kinases, Ion Channels, Proteases and Nuclear Receptors. Additional
AurSCOPE® databases relate to safety, toxicology, and pharmacokinetics (ADME,
hERG). Consolidating all the therapeutic targets, the AurSCOPE® Global
Pharmacology Space (GPS) provides researchers with the most comprehensive
available coverage of the "druggable" genome. Applications include AurQUEST®,
the web-based query tool, DDI Predict for drug-drug interactions, and
AurPROFILER®, the compound profiling visualization tool. Headquartered in Paris,
France, Aureus Pharma`s information solutions are proven to streamline the
discovery process for many of the world`s most successful biopharmaceutical
companies and prestigious research institutions.

See www.aureus-pharma.com for more information

Press and Analysts Contact
Andrew Lloyd & Associates
Neil Hunter / Andrew Lloyd
neil@ala.com / allo@ala.com
Tel +44 1273 675100

Copyright Business Wire 2009